54127-30-9

Basic information

• Product Name: 5,6-DICHLORO-3-PYRIDINEMETHANOL
• Synonyms: 2,3-DICHLORO-5-HYDROXYMETHYLPYRIDINE;5,6-DICHLORO-3-PYRIDINEMETHANOL;5,6-DICHLORONICOTINYL ALCOHOL;Dichloropyridinemethanol;5,6-dichloro-3-pyridinemethanol96+%;(5,6-dichloropyridin-3-yl)methanol;2,3-Dichloro-5-(hydroxymethyl)pyridine 95+%;2,3-Dichloro-5-hydroxymethylpyridine 5,6-Dichloronicotinyl Alcohol
• CAS NO: 54127-30-9
• Molecular Formula: C₆H₅Cl₂NO
• Molecular Weight: 178.02
• Product Categories: Chloropyridines;Halopyridines
• Mol File: 54127-30-9.mol
• Article Data: 14

Chemical Properties

• Melting Point: 76°C
• Boiling Point: 297.7°Cat760mmHg
• Flash Point: 133.9°C
• Appearance: /
• Density: 1.478
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 12.96±0.10(Predicted)
• CAS DataBase Reference: 5,6-DICHLORO-3-PYRIDINEMETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-DICHLORO-3-PYRIDINEMETHANOL(54127-30-9)
• EPA Substance Registry System: 5,6-DICHLORO-3-PYRIDINEMETHANOL(54127-30-9)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 54127-30-9(Hazardous Substances Data)

Usage

Uses

5,6-Dichloro-3-pyridinemethanol acts as a novel CXCR3 (CXC chemokine receptor) inhibitor. It also is used in the synthesis of pyridine-based histone deacetylase inhibitors.

InChI:InChI=1/C6H5Cl2NO/c7-5-1-4(3-10)2-9-6(5)8/h1-2,10H,3H2

Upstream product

• 71690-05-6 5,6-dichloro-pyridine-3-carbaldehyde 
• 41667-95-2 5,6-dichloronicotinic acid 
• 56055-54-0 methyl 2,3-dichloro-pyridine-5-carboxylate 
• 401566-69-6 ethyl 5,6-dichloronicotinate 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 13292-87-0 dimethyl sulfide borane 
• 54127-29-6 5,6-dichloronicotinoyl chloride 

Downstream Products

• 132865-53-3 (5-chloro-6-methoxy-pyridin-3-yl)-methanol 
• 1629240-47-6 C₂₂H₂₀N₂O₂ 
• 1384262-62-7 3-phenoxymethyl-6,7-dihydro-5H-[1,7]naphthyridin-8-one 
• 1384262-63-8 7-methyl-3-(phenoxymethyl)-6,7-dihydro-1,7-naphthyridin-8(5H)-one 
• 1616293-34-5 3-phenoxymethyl-7R-(1,2,2-trimethyl-propyl)-6,7-dihydro-5H-[1,7]naphthyridin-8-one 
• 1073616-83-7 3-chloro-5-(hydroxymethyl)-N-[4-(trifluoromethyl)phenyl]-3',6'-dihydro-(2,4'-bipyridine)-1'(2'H)-carboxamide 
• 1384262-85-4 3-(2-oxo-ethyl)-5-phenoxymethyl-pyridine-2-carboxylic acid methyl ester 
• 1384262-84-3 3-allyl-5-phenoxymethyl-pyridine-2-carboxylic acid methyl ester 
• 1384262-83-2 3-chloro-5-phenoxymethyl-pyridine-2-carboxylic acid methyl ester 
• 1384262-82-1 3-chloro-5-phenoxymethyl-pyridine-2-carboxylic acid 
• 1384262-81-0 3-chloro-5-phenoxymethyl-pyridine-2-carbonitrile 
• 1384262-42-3 7-(4-fluorophenyl)-3-phenoxymethyl-6,7-dihydro-5H-[1,7]-naphthyridin-8-one 
• 1355488-86-6 tert-butyl 4-((5,6-dichloropyridin-3-yl)methoxy)-2,5-difluorobenzoate 
• 1308279-71-1 ethyl (E)-3-{2-[3'-(1-adamantyl)-4'-benzyloxyphenyl]-3-chloro-5-pyridinyl}-2-propenoate 

Relevant articles and documents

BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceuticall acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising th

NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY

The present invention relates to aryl sulfones and related compounds that are modulators of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these modulators, and methods of modulating ROR-gamma receptors using them. Also provided are methods of using aryl sulfones and related compounds as modulators of ROR-gamma to treat ROR-gamma mediated diseases

NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS

In one aspect, the invention relates to naphthyridinone analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.